{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '7.2.3.', 'Corneal Supportive Care Guidelines', 'Corneal events, which commonly manifests as a superficial microcystic keratopathy, has', 'been observed with antibody drug conjugates, including those conjugated to MMAF.', 'Further information regarding corneal event associated with GSK2857916, including a', 'GSK corneal event scale and prophylactic measures are in Appendix 9.', 'Sites are required to establish a close collaboration with an ophthalmologist (or', 'optometrist, if an ophthalmologist is not available) who will be responsible for assessing', 'participants and managing those who develop a corneal event in close communication', 'with GSK Medical Monitor and possibly a GSK ophthalmologist.', 'Participants will be assessed by ophthalmologists (or optometrist, if an ophthalmologist is', 'not available) at baseline and every three weeks. If there are no corneal events at time of', 'the Cycle 4 exam, participants may have their ophthalmologic exams decreased to once', 'every 3 months. If a participant subsequently develops ocular symptoms, the participant', 'should be evaluated by an ophthalmologist (or optometrist, if an ophthalmologist is not', 'available). Intraocular pressure must be monitored if steroid eye drops are used', 'continuously for more than 7 days.', 'Participants who have corneal signs per the GSK Scale for corneal events present at end', 'of study will continue to be followed at 3 and 6 weeks after the EoT visit and then every', '6 weeks for up to 12 months, or until full resolution of ophthalmic changes, or deemed', 'clinically stable by an ophthalmologist/optometrist, whichever comes first.', 'At the selected sites, participants in the ocular sub-study will undergo additional', 'ophthalmic exams (see Section 9.2.10).', '7.3.', 'Method of Treatment Assignment', 'The Sponsor will supply a range of unique numbers to each site and participants eligible', 'for enrolment will be assigned a unique Participant Number by the site.', 'Before the study is initiated, log-in directions for the central Interactive Response', 'Technology (IRT) system will be provided to each site to be used to for study drug', 'supply.', 'Participant numbers are unique will not be reassigned to another participant if a', 'participant assigned a number is found to be a Screen Failure.', 'Participants will be assigned to study treatment in accordance with the randomization', 'schedule.', 'Participants will be identified by a unique participant number that will remain consistent', 'for the duration of the study.', 'Upon completion of all the required screening assessments, eligible participants will be', 'registered into the Registration and Medication Ordering System (RAMOS), the GSK', '62']['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Interactive Response Technology (IRT, by the investigator or authorized site staff.', 'RAMOS allows study sites to register and randomize participants, and also records', 'stratification information.', 'The following information for stratification must be entered into the system to obtain the', 'treatment assignment:', 'number of prior lines of therapy', 'cytogenetic risk categories (high risk defined as t(4;14), t(14;16), and 17p13del vs', 'non-high risk - all others);', 'Randomization will be done centrally using a randomization schedule generated by the', 'GSK Clinical Statistics Department, which will assign participants in a 1:1 ratio to:', 'Arm 1: 3.4 mg/kg IV Q3W', 'Arm 2: 2.5 mg/kg IV Q3W', 'Once a randomization number has been assigned it must not be re-assigned even in cases', 'of errors.', 'In the lyophilized cohort participants will be assigned the 3.4 mg/kg dose level, unless the', 'results of the IA indicate that it should not be continued. In that case, the 2.5 mg/kg dose', 'level will be assigned to participants.', 'RAMOS Study Specific User Guide and Clinical Support Helpdesk contact information', 'will be provided to the study site in the SRM.', '7.4.', 'Blinding', 'This will be an open-label, 2-arm monotherapy study with an additional independent', 'cohort enrolled after lyophilized product is available. Therefore, sponsor will have', 'access to the participant level data throughout the study. However, there will be no', 'intention to summarize and interpret data from the ongoing study at any time point except', 'the pre-defined analyses.', 'In the ocular sub-study of participants (Section 9.2.10 and Appendix 9), the treating', 'ophthalmologist will remain blinded as to which eye receives the prophylactic', 'corticosteroid treatment.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all study treatment received and any discrepancies are', 'reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only authorized', 'site staff may supply or administer study treatment. All study treatments must be stored', '63']\n\n###\n\n", "completion": "END"}